Melanie C. Smitt
- Cancer Research top 2%
- Breast Cancer Treatment Studies 19
- Oncology top 2%
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 6
- Peptidase Inhibition and Analysis 4
-
- Breast Lesions and Carcinomas 9
-
- Monoclonal and Polyclonal Antibodies Research 7
- Radiation top 5%
- Advanced Radiotherapy Techniques 8
-
- Head and Neck Cancer Studies 5
- Co-authors
- Ian E. KropAntonio González-Martı́nHans WildiersPatricia LoRussoJean-Marc FerreroSung‐Bae KimRobert W. CarlsonStefanie S. Jeffrey
- Partner nations
- United StatesSwitzerlandFrance
In The Last Decade
Melanie C. Smitt
42 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 78
- Cancer Research 897
- Oncology 1.4k
- Pathology and Forensic Medicine 656
- Radiology, Nuclear Medicine and Imaging 784
- Radiation 171
Countries citing papers authored by Melanie C. Smitt
This map shows the geographic impact of Melanie C. Smitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie C. Smitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie C. Smitt more than expected).
Fields of papers citing papers by Melanie C. Smitt
This network shows the impact of papers produced by Melanie C. Smitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie C. Smitt. The network helps show where Melanie C. Smitt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Melanie C. Smitt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialbreakdown → | 2017 | 371 |
| 2 | 2017 | 17 | |
| 3 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialbreakdown → | 2014 | 512 |
| 4 | 2014 | 91 | |
| 5 | 2010 | 58 | |
| 6 | 2007 | 91 | |
| 7 | 2007 | 13 | |
| 8 | 2006 | 2 | |
| 9 | 2004 | 1 | |
| 10 | 2003 | 125 | |
| 11 | 2003 | 2 | |
| 12 | 2003 | 3 | |
| 13 | 2001 | 68 | |
| 14 | 1999 | 8 | |
| 15 | 1999 | 27 | |
| 16 | 1997 | 37 | |
| 17 | 1997 | 44 | |
| 18 | 1995 | 326 | |
| 19 | 1994 | 19 | |
| 20 | 1993 | 82 |
About Melanie C. Smitt
Melanie C. Smitt is a scholar working on Cancer Research, Otorhinolaryngology and Radiation, having authored 45 papers that have together received 2.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (19 papers), HER2/EGFR in Cancer Research (14 papers), Breast Lesions and Carcinomas (9 papers), Advanced Radiotherapy Techniques (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer Treatment and Pharmacology (6 papers), Head and Neck Cancer Studies (5 papers) and Peptidase Inhibition and Analysis (4 papers). The work is most often cited by research in Cancer Research (897 citations), Oncology (1.4k citations) and Pathology and Forensic Medicine (656 citations). Melanie C. Smitt has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Ian E. Krop, Antonio González-Martı́n, Hans Wildiers, Patricia LoRusso, Jean-Marc Ferrero, Sung‐Bae Kim, Robert W. Carlson, Stefanie S. Jeffrey, Kent W. Nowels and Ron Yu. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.